| Literature DB >> 20353781 |
Lourdes Ruiz-Valdepeñas1, Cristina Benito, Rosa María Tolón, José Antonio Martínez Orgado, Julián Romero.
Abstract
The endocannabinoid system may be the target of novel therapies in a wide variety of diseases. Among them, those related with amyloid accumulation will be discussed in the present review. Several components of this system (CB1 and CB2 receptors, endocannabinoids, FAAH enzyme) may participate in different aspects of amyloid pathophysiology such as, for instance, synaptic activity, cell migration, cytokine production or phagocytic activity. Consistent with recent data, putative lines of research and hypothesis will be discussed. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20353781 DOI： 10.1016/j.expneurol.2010.03.024
Source DB: PubMed Journal: Exp Neurol ISSN： 0014-4886 Impact factor: 5.330